IP Library › Granted Patent US 10,279,030
Granted Patent B2
US 10,279,030 · App. 15/265,236 · Granted May 7, 2019

Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)

Inventors: SangKon Oh (Baltimore, MD); Dapeng Li (Davis, CA)
Assignee: Baylor Research Institute
A61K39/145A61K47/6849A61K51/1027C07K14/005C07K14/195C07K14/37C07K14/405C07K14/435C07K16/28C12N5/0639C12N7/00A61K2039/5154C07K2317/24C07K2317/33C07K2317/56C07K2317/74C07K2317/75C07K2317/92C12N2760/16122C12N2760/16134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,279,030
App. No.
15/265,236
Granted
May 7, 2019
Kind
B2
Abstract

The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.

Claims (6)

1. A method of delivering an autoantigen to antigen presenting cells in a subject, comprising the step of administering to the subject an effective amount of a composition comprising a recombinant fusion protein, said fusion protein comprising an anti-human dendritic cell asialoglycoprotein receptor (ASGPR) antibody or an antigen binding fragment thereof and one or more autoimmune antigens, wherein the antibody or fragment thereof comprises an immunoglobulin heavy chain selected from the group consisting of SEQ ID NO: 5, 7, 9, and 11.

2. The method of claim 1 , wherein the subject has an autoimmune disorder.

3. The method of claim 2 , wherein the autoimmune disorder is multiple sclerosis.

4. The method of claim 2 , wherein the autoimmune disorder is systemic lupus erythematosus (SLE).

5. The method of claim 2 , wherein the autoimmune disorder is myasthenia gravis (MG).

6. The method of claim 2 , wherein the autoantigen is Smith protein, RNP ribonucleoprotein, SS-A protein, SS-B protein, acetylcholine receptor, luteinizing hormone, follicular stimulating hormone, testosterone, growth hormone, prolactin, glutamic acid decarboxylase 65 (GAD 65), myelin basic protein, myelin proteolipid protein, thyroglobulin, thyroid stimulating hormone (TSH) receptor or a combination thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 7, 2018
From: BAYLOR RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045518/0119 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2016
From: OH, SANGKON; LI, DAPENG
To: BAYLOR RESEARCH INSTITUTE
Reel/Frame 039741/0417 →
Continuity (5)
Continuation 14254206 · Apr 16, 2014
Continuation 13551198 · Jul 17, 2012
Division 12025010 · Feb 2, 2008
Provisional Application 60888036 · Feb 2, 2007
Related Publication 20160375126A1 · Dec 29, 2016
Cited By (1)
US 12,714,745